Prelude Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Prelude Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.7K	Buy	+20,400	New	+$52.7K	﹤0.01%	1128
2025 Q2	–	Sell	-18,710	Closed	-$29.7K	–	1437
2025 Q1	$29.7K	Sell	18,710 -800	-4%	-$1.73K	﹤0.01%	1118
2024 Q4	$59.1K	Buy	19,510 +4,300	+28%	+$14.1K	﹤0.01%	1139
2024 Q3	$56K	Buy	+15,210	New	+$55.3K	﹤0.01%	1207
2023 Q4	–	Sell	-10,190	Closed	-$204K	–	1398
2023 Q3	$204K	Buy	10,190 +173	+2%	+$4.39K	0.01%	891
2023 Q2	$283K	Buy	+10,017	New	+$240K	0.02%	677

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Prelude Capital Management's ZNTL Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 20,400 shares worth $47.7K. The stake represents ﹤0.01% of the portfolio and ranks #1128 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in ZNTL as recently as Q1 2025.

Prelude Capital Management first reported a position in ZNTL in Q2 2023 and has held it in 6 quarters since. The position peaked at $283K in Q2 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Prelude Capital Management held 20,400 shares of Zentalis Pharmaceuticals worth $47.7K as of Q1 2026.
Zentalis Pharmaceuticals was a new Prelude Capital Management position in Q1 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1128 holding.
Prelude Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
Prelude Capital Management's Zentalis Pharmaceuticals position peaked at $283K in Q2 2023.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.